Articles By Janet Pope, MD, MPH, FRCPC

CAR T on purple background

¿Cuántos CAR-T necesitamos probar?

By Janet Pope, MD, MPH, FRCPC

La terapia CAR-T en #EULAR2026 planteó tantas preguntas como respuestas. Esto es lo que sabemos, lo que todavía nos preguntamos y por qué las respuestas son importantes.

Read Article
CAR T on purple background

How many CAR-T’s do we need to test drive?

By Janet Pope, MD, MPH, FRCPC

CAR-T at #EULAR2026 raised as many questions as it answered. Here's what we know, what we're still asking, and why the answers matter.

Read Article
lupus SLE

¡Cómo tratar el LES en 2026 y más allá!

By Janet Pope, MD, MPH, FRCPC

Hay tantos ensayos clínicos sobre el LES y, en el último año, se han sugerido muchas ideas nuevas.

Read Article
lupus SLE

How to treat SLE in 2026 and beyond!

By Janet Pope, MD, MPH, FRCPC

There are so many SLE trials, and over the last year, many new ideas have been suggested.

Read Article
change,future,lens,clarity

Predicciones ‘sólidas’ de tratamiento en la miositis inflamatoria

By Janet Pope, MD, MPH, FRCPC

Presentado en el EULAR 2026 de Londres, el brepocitinib, un inhibidor dual de TYK2/JAK1, con el exitoso ensayo de fase 3 VALOR, demostró una mejora significativa de los síntomas cutáneos y musculares en la dermatomiositis (DM).

Read Article
change,future,lens,clarity

‘Strong’ treatment predictions in inflammatory myositis

By Janet Pope, MD, MPH, FRCPC

Presented at EULAR 2026 London, Brepocitinib dual TYK2/JAK1 inhibitor with successful Phase 3 VALOR trial demonstrating significant improvement in skin and muscle symptoms in dermatomyositis (DM).

Read Article
syringe, pill, DMARD, Treatment, therapy

What should head-to-head studies in inflammatory arthritis teach us?

By Janet Pope, MD, MPH, FRCPC

The multimillion dollar question for inflammatory arthritis prescriptions is: which drug should I use next?

Read Article
human figures on blue circle

IgG4: Rare, but new treatments on the horizon

By Janet Pope, MD, MPH, FRCPC

IgG4 is a rare autoimmune disease with excessive IgG4 immunoglobulins that can affect multiple organs yielding plasma cell deposition (inflammation) and fibrosis.

Read Article
Big data

Rheumatoid arthritis and the ‘big bang’ at the ACR!

By Janet Pope, MD, MPH, FRCPC

Is there ‘bang for the buck’ using big data to help predict who will develop RA in at-risk populations and similarly to predict response to csDMARDs, TNFi and JAKi in RA?

Read Article
magnifying glass with IPAF

What is IPAF?

By Janet Pope, MD, MPH, FRCPC

Idiopathic Interstitial Pneumonia with Autoimmune Features - or IPAF - describes patients with interstitial pneumonia with autoimmune features, but they don’t meet a diagnosis of a CTD.

Read Article
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Profile picture for user Janet Pope, MD, MPH, FRCPC
  • Janet Pope, MD, MPH, FRCPC

  • Dr. Janet Pope is a Professor of Medicine in the Division of Rheumatology at the University of Western Ontario (UWO), Schulich School of Medicine, London, Ontario, Canada.  She is the Division Head in Rheumatology at St. Joseph's Health Centre, London. Her research includes studies in scleroderma, SLE and RA, including outcome measurements, clinical trials and disease manifestations. She has published over 450 peer-reviewed articles, 15 chapters, 500 abstracts and several Cochrane meta-analysis reviews. Mentoring of research students and trainees numbers more than 125. She has received the Distinguished Investigator Award from the Canadian Rheumatology Association, Rheumatologist of the Year from the Ontario Rheumatology Association, Department of Medicine Research Achievement Award, and the Dean’s Award of Excellence in Research. She has been inducted into the Canadian Academy of Health Sciences.

     

×